Novel surface-modified nanostructured lipid carriers with partially deacetylated water-soluble chitosan for efficient ocular delivery

Journal of Pharmaceutical Sciences

Volumn 101, Issue 3, 2012, Pages 1040-1049

  Tian, Baocheng ^a   Luo, Qiuhua ^a   Song, Shuangshuang ^a   Liu, Dandan ^a   Pan, Hao ^a   Zhang, Wenji ^a   He, Ling ^a   Ma, Shilin ^a   Yang, Xinggang ^a   Pan, Weisan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Biomaterials; Chitosan; Coating; Nanostructured lipid carriers; Ocular drug delivery; Ocular irritation; Permeability; Precorneal retention; Solubility; Transcorneal permeation

Indexed keywords

CHITOSAN DERIVATIVE; FLURBIPROFEN; NANOCARRIER; NANOSPHERE; NANOSTRUCTURED LIPID CARRIER; PARTIALLY DEACETYLATED WATER SOLUBLE CHITOSAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORNEA; CORNEA PERMEABILITY; CRYSTAL STRUCTURE; DEACETYLATION; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RETENTION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; EMULSION; EXPERIMENTAL RABBIT; EYE IRRITATION; GAMMA SCINTIGRAPHY; IN VIVO STUDY; MALE; MELT EMULSIFICATION; NANOENCAPSULATION; NONHUMAN; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84855864937     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22813     Document Type: Article

References (37)

1. Gratieri T, Gelfuso GM, Rocha EM, Sarmento VH, Freitas OD, Lopez RFV. 2010. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Eur J Pharm Biopharm 75:186-193.
2. Li X, Nie SF, Kong J, Li N, Ju CR, Pan WS. 2008. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 363:177-182.
3. Diebold Y, Jarrin M, Saez V, Carvalho ELS, Orea M, Calonge M, Seijo B, Alonso MJ. 2007. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 28:1553-1564.
4. Ludwig A. 2005. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliver Rev 57:1595-1639.
5. Salminen L. 1990. Review: Systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol 6:243-249.
6. Swarnali DM, Preeti KS. 2011. Nanosuspension: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to amphotericin B. Nanomedicine 7:242-247.
7. Pignatello R, Bucolo C, Ferrara P, Maltese A, Puleo A, Puglisi G. 2002. Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen. Eur J Pharm Sci 16:53-61.
8. Gan L, Han S, Shen JQ, Zhu JB, Zhu CJ, Zhang XX, Gan Y. 2010. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. Int J Pharm 396:179-187.
9. Gavini E, Chetoni P, Cossu M, Alvarez MG, Saettone MF, Giunchedi P. 2004. PLGA microspheres for the ocular delivery of a peptide drug, vancomycin using emulsification/spray-drying as the preparation method: in vitro/in vivo studies. Eur J Pharm Biopharm 57:207-212.
10. Civiale C, Licciardi M, Cavallaro G, Giammona G, Mazzone MG. 2009. Polyhydroxyethylaspartamide-based micelles for ocular drug delivery. Int J Pharm 378:177-186.
11. Qi HY, Chen WW, Huang CY, Li L, Chen CM, Li WM, Wu CJ. 2007. Development of a poloxamer analogs/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin. Int J Pharm 337:178-187.
12. Alany RG, Rades T, Nicoll J, Tucker IG, Davies NM. 2006. W/O microemulsions for ocular delivery: Evaluation of ocular irritation and precorneal retention. J Control Release 111:145-152.
13. Chan J, Maghraby GMM, Craig JP, Alany RG. 2007. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm 328:65-71.
14. Fresta M, Panico AM, Bucolo C, Giannavola C, Puglisi G. 1999. Characterization and in-vivo ocular absorption of liposome-encapsulated acyclovir. J Pharm Pharmacol 51:565-576.
15. Law SL, Huang KJ, Chiang CH. 2000. Acyclovir-containing liposomes for potential ocular delivery: Corneal penetration and absorption. J Control Release 63:135-140.
16. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. 2002. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 238:241-245.
17. Muller RH, Radtke M, Wissing SA. 2002. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 242:121-128.
18. Muller RH, Radtke M, Wissing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliver Rev 54:S131-S155.
19. Majumdar S, Hippalgaonkar K, Repka MA. 2008. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. Int J Pharm 348:175-178.
20. Di Colo G, Zambito Y, Zaino C. 2008. Polymeric enhancers of mucosal epithelia permeability: Synthesis, transepithelial penetration-enhancing properties, mechanism of action, safety issues. J Pharm Sci 97:1652-1680.
21. Lehr CM, Bouwstra JA, Schacht EH, Junginger HE. 1992. in vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int J Pharm 78:43-48.
22. Felt O, Furrer P, Mayer J, Plazonnet B, Buri P, Gurny R. 1999. Topical use of chitosan in ophthalmology: Tolerance assessment and evaluation of precorneal retention. Int J Pharm 180:185-193.
23. Zambito Y, Zaino C, Di Colo G. 2006. Effects of N-trimethylchitosan on transcellular and paracellular transcorneal drug transport. Eur J Pharm Biopharm 64:16-25.
24. Di Colo G, Zambito Y, Burgalassi S, Nardini I, Saettone MF. 2004. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int J Pharm 273:37-44.
25. Kurita K, Kamiya M, Nishimura SI. 1991. Solubilization of a rigid polysaccharide: Controlled partial N-acetylation of chitosan to develop solubility. Carbohyd Polym 16:83-92.
26. Wang J, Liu CS, Chi P. 2008. Aggregate formation and surface activity of partially deacetylated water-soluble chitin. Res Chem Intermed 34:169-179.
27. Gao Q, Wan AJW. 2006. Effects of molecular weight, degree of acetylation and ionic strength on surface tension of chitosan in dilute solution. Carbohyd Polym 64:29-36.
28. Luo QH, Zhao JM, Zhang XR, Pan WS. 2011. Nanostructured lipid carrier (NLC) coated with chitosan oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 403:185-191.
29. Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, Pan YS, Tang X. 2010. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability. Int J Pharm 394:179-185.
30. Mccarey BE, Edelhauser HF, Van Horn DL. 1973. Functional and structural changes in the corneal endothelium during in vitro perfusion. Invest Ophthalmol Vis Sci 12:410-417.
31. Schoenwald RD, Huang HS. 1983. Corneal penetration behavior of β-blocking agents I: Physicochemical factors. J Pharm Sci 72:1266-1272.
32. Meseguer G, Gurny R, Buri P, Rozier A, Plazonnet B. 1993. Gamma scintigraphic study of precorneal drainage and assessment of miotic response in rabbits of various ophthalmic formulations containing pilocarpine. Int J Pharm 95:229-234.
33. Li N, Zhuang CY, Wang M, Sun XY, Nie SF, Pan WS. 2009. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm 379:131-138.
34. Wei G, Xu H, Ding PT, Li SM, Zheng JM. 2002. Thermosetting gels with modulated gelation temperature for ophthalmic use: The rheological and gamma scintigraphic studies. J Control Release 83:65-74.
35. Liu ZD, Li JW, Nie SF, Liu H, Ding PT, Pan WS. 2006. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. Int J Pharm 315:12-17.
36. Nagarsenker MS, Londhe VY, Nadkarni GD. 1999. Preparation and evaluation of liposomal formulations of tropicamide for ocular delivery. Int J Pharm 190:63-71.
37. Smart JD. 2005. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev 57:1556-1568.